Yahoo Finance

ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV INFECTIONS ...

ALX-0171 had an immediate and significant impact on viral replication and an encouraging initial therapeutic effect in a Phase IIa study in hospitalised infants with a RSV infection [1] GHENT, Belgium ...
Yahoo Finance

ABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIb RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171

GHENT, Belgium, 30 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it has successfully completed patient recruitment in the Phase IIb RESPIRE dose-ranging efficacy study ...
PharmiWeb

Atriva Therapeutics Announces Publication of Proof of Concept (POC) / Phase 2a RESPIRE Study Data with Zapnometinib in Patients Hospitalized with COVID-19

Atriva Therapeutics announces publication of results from the Phase 2a RESPIRE study in eClinicalMedicine (part of THE LANCET Discovery Science) Results reflect clinically relevant efficacy for ...
Finanznachrichten

Ablynx: ABLYNX INITIATES THE PHASE IIb "RESPIRE" STUDY OF ITS WHOLLY-OWNED, FIRST-IN-CLASS, INHALED ANTI-RSV NANOBODY, ALX-0171, FOR THE TREATMENT OF RSV ...

About the RESPIRE study The primary objective of the recently reported first-in-infant Phase I/IIa study in 53 hospitalised RSV-infected infants, aged 1-24 months, was to evaluate the safety and ...
Finanznachrichten

Ablynx: ABLYNX COMPLETES PATIENT RECRUITMENT IN THE PHASE IIb RESPIRE STUDY OF ITS INHALED ANTI-RSV NANOBODY ALX-0171

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 30 April 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that it has successfully completed patient recruitment in the ...